Hesperadin
Based on 12 publication(s) in Google Scholar
Hesperadin is an ATP competitive indolinone inhibitor of Aurora A and B. Hesperadin inhibits Aurora B with an IC50 of 250 nM. Hesperadin inhibits the growth of Trypanosoma brucei by blocking nuclear division and cytokinesis. Hesperadin also is a broad-spectrum influenza antiviral.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.89%
- No. CAS: 422513-13-1
- Fòrmula: C29H32N4O3S
- Peso molecular:516.65
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Kinase Inhibitor Library
HY-L009
-
Anti-Cancer Compound Library
HY-L025
-
Antiviral Compound Library
HY-L027
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Anti-Blood Cancer Compound Library
HY-L079
-
Antiparasitic Compound library
HY-L082
-
Heterocyclic Compound Library
HY-L138
-
Highly Selective Inhibitors Library
HY-L158
-
Cell Death Library
HY-L162
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Anti-Hematopathy Compound Library
HY-L171
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
Epigenetics Compound Library Mini
HY-L005M
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) Hesperadin
More- Nat Commun. 2025 Sep 29;16(1):8598. [Abstract]
- Adv Sci (Weinh). 2025 Jan 22:e2414518. [Abstract]
- Adv Sci (Weinh). 2022 Oct 30;e2205091. [Abstract]
- Cell Commun Signal. 2025 Oct 2;23(1):409. [Abstract]
- Sci Signal. 2025 Feb 18;18(874):eadg4626. [Abstract]
- Antioxid Redox Signal. 2025 Jan;42(1-3):115-132. [Abstract]
- Int J Mol Sci. 2025 Aug 20;26(16):8052. [Abstract]
- Sci Rep. 2021 Jan 27;11(1):2283. [Abstract]
- Brain Res Bull. 2021 Dec:177:31-38. [Abstract]
- Behav Neurol. 2020 Feb 3;2020:2476861. [Abstract]
- Exp Cell Res. 2021 Sep 1;406(1):112741. [Abstract]
- bioRxiv. 2024 May 31.
Customer Validation & Images
-
WB
Ver todos los productos específicos de isoformas Aurora Kinase
MoreVer todos los productos específicos de isoformas Parasite
More
Actividad biológica
|
Trypanosoma |
Aurora B 250 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDCK | CC50 |
21.3 μM
Compound: 68
|
Cytotoxicity against MDCK cells
Cytotoxicity against MDCK cells
|
[PMID: 33539089] |
Hesperadin (10-100 nM) inhibits the Aurora kinase-1 (TbAUK1)-mediated phosphoryation of trypanosome histone H3 (TbH3) in a dose dependent manner, with an IC50 of 40 nM[1].
Hesperadin (0.01-10 μM; 24 or 48 hours) inhibits growth of bloodstream forms (BF) and procyclic forms (PF) cultures[1].
Hesperadin (100-200 nM; 24-72 hours) alters cell morphology and inhibits cell cycle progression similar to the RNAi knockdown of TbAUK1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:M110 cells
-
Concentration:0.01, 0.1, 1, 10 μM
-
Incubation Time:24 hours or 48 hours
-
Result:Inhibiting growth of BF cultures with IC50 of 50 nM, while the inhibition of PF growth required approximately 11-fold more Hesperadin, with IC50 of 550 nM.
-
Cell Line:M110 cells
-
Concentration:100, 200 nM
-
Incubation Time:24, 48, 72 hours
-
Result:Had a strong effect on cell growth and mitotic progression at 100-200 nM.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:6-week-old female nude mice injected GBM cells[2]
-
Dosage:20 mg/kg/d
-
Administration:I.v. injection
-
Result:Increased the survival of xenograft mice models.
Chemical Information
-
No. CAS 422513-13-1
-
Appearance Solid
-
Peso molecular 516.65
-
Fòrmula C29H32N4O3S
-
Color Light yellow to yellow
-
SMILES
O=C1NC2=CC=C(C=C2/C1=C(NC3=CC=C(C=C3)CN4CCCCC4)\C5=CC=CC=C5)NS(CC)(=O)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Cytoplasmic TRIM24 promotes colorectal cancer cell proliferation by activating Wnt/β-catenin signaling. [Abstract]2025 Sep 29;16(1):8598. PMID: 41022821 -
Adv Sci (Weinh)
Ischemic Area-Targeting and Self-Monitoring Nanoprobes Ameliorate Myocardial Ischemia/Reperfusion Injury by Scavenging ROS and Counteracting Cardiac Inflammation. [Abstract]2025 Jan 22:e2414518. PMID: 39840521 -
Adv Sci (Weinh)
N6 -Methyladenosine-Modified CBX1 Regulates Nasopharyngeal Carcinoma Progression Through Heterochromatin Formation and STAT1 Activation. [Abstract]2022 Oct 30;e2205091. PMID: 36310139 -
Cell Commun Signal
2025 Oct 2;23(1):409. PMID: 41039590 -
Sci Signal
Sustained chromosomal passenger complex activity preserves the pluripotency of human embryonic carcinoma cells. [Abstract]2025 Feb 18;18(874):eadg4626. PMID: 40136047 -
Antioxid Redox Signal
CARD11-BCL10-MALT1 complex-dependent MALT1 activation facilitates myocardial oxidative stress in doxorubicin-treated mice via enhancing k48-linked ubiquitination of Nrf2. [Abstract]2025 Jan;42(1-3):115-132. PMID: 38814831 -
Int J Mol Sci
STK26 Promotes the Stabilization of ATF6 to Facilitate the Progression of Colorectal Cancer. [Abstract]2025 Aug 20;26(16):8052. PMID: 40869379 -
Sci Rep
Depletion of Survivin suppresses docetaxel-induced apoptosis in HeLa cells by facilitating mitotic slippage. [Abstract]2021 Jan 27;11(1):2283. PMID: 33504817 -
Brain Res Bull
MST4 attenuates NLRP3 inflammasome-mediated neuroinflammation and affects the prognosis after intracerebral hemorrhage in mice. [Abstract]2021 Dec:177:31-38. PMID: 34534636 -
Behav Neurol
MST4 Kinase Inhibitor Hesperadin Attenuates Autophagy and Behavioral Disorder via the MST4/AKT Pathway in Intracerebral Hemorrhage Mice. [Abstract]2020 Feb 3;2020:2476861. PMID: 32089749
Hesperadin purchased from MedChemExpress. Usage Cited in: Behav Neurol. 2020 Feb 3;2020:2476861. [Abstract]
Administration of hesperadin influences endogenous expression of MST4, pAKT, AKT, and LC3 12 h following ICH. Representative western blot bands for MST4, pAKT, AKT, and LC3 expression in sham and ICH mice 12 h following ICH.
-
Exp Cell Res
RNA-binding protein RNPC1 acts as an oncogene in gastric cancer by stabilizing aurora kinase B mRNA. [Abstract]2021 Sep 1;406(1):112741. PMID: 34302858 -
Solvente y solubilidad
DMSO : ≥ 100 mg/mL (193.55 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.84 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (288 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Neal J, et, al. The cell cycle as a therapeutic target against Trypanosoma brucei: Hesperadin inhibits Aurora kinase-1 and blocks mitotic progression in bloodstream forms. Mol Microbiol. 2009 Apr; 72(2): 442-58. [Content Brief]
[2]. Wahafu A, et, al. Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide. Pathol Res Pract. 2019 Nov; 215(11): 152617. [Content Brief]
[3]. Hu Y, et, al. Chemical Genomics Approach Leads to the Identification of Hesperadin, an Aurora B Kinase Inhibitor, as a Broad-Spectrum Influenza Antiviral. Int J Mol Sci. 2017 Sep 8;18(9):1929. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9355 mL | 9.6777 mL | 19.3555 mL | 48.3887 mL |
| 5 mM | 0.3871 mL | 1.9355 mL | 3.8711 mL | 9.6777 mL | |
| 10 mM | 0.1936 mL | 0.9678 mL | 1.9355 mL | 4.8389 mL | |
| 15 mM | 0.1290 mL | 0.6452 mL | 1.2904 mL | 3.2259 mL | |
| 20 mM | 0.0968 mL | 0.4839 mL | 0.9678 mL | 2.4194 mL | |
| 25 mM | 0.0774 mL | 0.3871 mL | 0.7742 mL | 1.9355 mL | |
| 30 mM | 0.0645 mL | 0.3226 mL | 0.6452 mL | 1.6130 mL | |
| 40 mM | 0.0484 mL | 0.2419 mL | 0.4839 mL | 1.2097 mL | |
| 50 mM | 0.0387 mL | 0.1936 mL | 0.3871 mL | 0.9678 mL | |
| 60 mM | 0.0323 mL | 0.1613 mL | 0.3226 mL | 0.8065 mL | |
| 80 mM | 0.0242 mL | 0.1210 mL | 0.2419 mL | 0.6049 mL | |
| 100 mM | 0.0194 mL | 0.0968 mL | 0.1936 mL | 0.4839 mL |
Hesperadin Related Classifications
HY-12054 Related Classifications
Powered by Bioz